298 related articles for article (PubMed ID: 27440518)
1. Dose reduction of edoxaban preserves efficacy and safety for the treatment of venous thromboembolism. An analysis of the randomised, double-blind HOKUSAI VTE trial.
Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MP; Cohen AT; Meyer G; Grosso MA; Raskob G; Weitz JI; Zhang G; Buller H
Thromb Haemost; 2016 Sep; 116(4):747-53. PubMed ID: 27440518
[TBL] [Abstract][Full Text] [Related]
2. Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial.
Raskob GE; van Es N; Segers A; Angchaisuksiri P; Oh D; Boda Z; Lyons RM; Meijer K; Gudz I; Weitz JI; Zhang G; Lanz H; Mercuri MF; Büller HR;
Lancet Haematol; 2016 Aug; 3(8):e379-87. PubMed ID: 27476789
[TBL] [Abstract][Full Text] [Related]
3. Recurrent venous thromboembolism in patients with pulmonary embolism and right ventricular dysfunction: a post-hoc analysis of the Hokusai-VTE study.
Brekelmans MP; Ageno W; Beenen LF; Brenner B; Buller HR; Chen CZ; Cohen AT; Grosso MA; Meyer G; Raskob G; Segers A; Vanassche T; Verhamme P; Wells PS; Zhang G; Weitz JI
Lancet Haematol; 2016 Sep; 3(9):e437-45. PubMed ID: 27570090
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of edoxaban for treatment of venous thromboembolism: a subanalysis of East Asian patients in the Hokusai-VTE trial.
Nakamura M; Wang YQ; Wang C; Oh D; Yin WH; Kimura T; Miyazaki K; Abe K; Mercuri M; Lee LH; Segers A; Büller H
J Thromb Haemost; 2015 Sep; 13(9):1606-14. PubMed ID: 26179767
[TBL] [Abstract][Full Text] [Related]
5. Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study.
Raskob G; Ageno W; Cohen AT; Brekelmans MP; Grosso MA; Segers A; Meyer G; Verhamme P; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Lancet Haematol; 2016 May; 3(5):e228-36. PubMed ID: 27132697
[TBL] [Abstract][Full Text] [Related]
6. Outpatient Management in Patients with Venous Thromboembolism with Edoxaban: A Post Hoc Analysis of the Hokusai-VTE Study.
Medina A; Raskob G; Ageno W; Cohen AT; Brekelmans MPA; Chen CZ; Grosso MA; Mercuri MF; Segers A; Verhamme P; Vanassche T; Wells PS; Lin M; Winters SM; Weitz JI; Büller HR
Thromb Haemost; 2017 Dec; 117(12):2406-2414. PubMed ID: 29212128
[TBL] [Abstract][Full Text] [Related]
7. [Hokusai-VTE: edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism].
Sprynger M
Rev Med Liege; 2013 Oct; 68(10):548-51. PubMed ID: 24298731
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study.
Preblick R; Kwong WJ; White RH; Goldhaber SZ
Hosp Pract (1995); 2015; 43(5):249-57. PubMed ID: 26549305
[TBL] [Abstract][Full Text] [Related]
9. Impact of age, comorbidity, and polypharmacy on the efficacy and safety of edoxaban for the treatment of venous thromboembolism: An analysis of the randomized, double-blind Hokusai-VTE trial.
Vanassche T; Verhamme P; Wells PS; Segers A; Ageno W; Brekelmans MPA; Chen CZ; Cohen AT; Grosso MA; Medina AP; Mercuri MF; Winters SM; Zhang G; Weitz JI; Raskob GE; Büller HR
Thromb Res; 2018 Feb; 162():7-14. PubMed ID: 29248859
[TBL] [Abstract][Full Text] [Related]
10. Edoxaban for the long-term treatment of venous thromboembolism: rationale and design of the Hokusai-venous thromboembolism study--methodological implications for clinical trials.
Raskob G; Büller H; Prins M; Segers A; Shi M; Schwocho L; van Kranen R; Mercuri M;
J Thromb Haemost; 2013 Jul; 11(7):1287-94. PubMed ID: 23574579
[TBL] [Abstract][Full Text] [Related]
11. Direct factor Xa inhibitor edoxaban: from bench to clinical practice.
Brekelmans M; Middeldorp S; Coppens M
Expert Rev Hematol; 2015 Dec; 8(6):707-25. PubMed ID: 26560872
[TBL] [Abstract][Full Text] [Related]
12. Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial.
Ruff CT; Giugliano RP; Braunwald E; Morrow DA; Murphy SA; Kuder JF; Deenadayalu N; Jarolim P; Betcher J; Shi M; Brown K; Patel I; Mercuri M; Antman EM
Lancet; 2015 Jun; 385(9984):2288-95. PubMed ID: 25769361
[TBL] [Abstract][Full Text] [Related]
13. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism.
; Büller HR; Décousus H; Grosso MA; Mercuri M; Middeldorp S; Prins MH; Raskob GE; Schellong SM; Schwocho L; Segers A; Shi M; Verhamme P; Wells P
N Engl J Med; 2013 Oct; 369(15):1406-15. PubMed ID: 23991658
[TBL] [Abstract][Full Text] [Related]
14. Extended treatment with edoxaban in cancer patients with venous thromboembolism: A post-hoc analysis of the Hokusai-VTE Cancer study.
Di Nisio M; van Es N; Carrier M; Wang TF; Garcia D; Segers A; Weitz J; Buller H; Raskob G
J Thromb Haemost; 2019 Nov; 17(11):1866-1874. PubMed ID: 31271705
[TBL] [Abstract][Full Text] [Related]
15. Genetics and clinical response to warfarin and edoxaban in patients with venous thromboembolism.
Vandell AG; Walker J; Brown KS; Zhang G; Lin M; Grosso MA; Mercuri MF
Heart; 2017 Nov; 103(22):1800-1805. PubMed ID: 28689179
[TBL] [Abstract][Full Text] [Related]
16. Edoxaban: A Review in Deep Vein Thrombosis and Pulmonary Embolism.
Shirley M; Dhillon S
Drugs; 2015 Nov; 75(17):2025-34. PubMed ID: 26546477
[TBL] [Abstract][Full Text] [Related]
17. Clinical impact and course of major bleeding with edoxaban versus vitamin K antagonists.
Brekelmans MP; Bleker SM; Bauersachs R; Boda Z; Büller HR; Choi Y; Gallus A; Grosso MA; Middeldorp S; Oh D; Raskob G; Schwocho L; Cohen AT
Thromb Haemost; 2016 Jul; 116(1):155-61. PubMed ID: 27010092
[TBL] [Abstract][Full Text] [Related]
18. Edoxaban for treatment of venous thromboembolism in patients with cancer. Rationale and design of the Hokusai VTE-cancer study.
van Es N; Di Nisio M; Bleker SM; Segers A; Mercuri MF; Schwocho L; Kakkar A; Weitz JI; Beyer-Westendorf J; Boda Z; Carrier M; Chlumsky J; Décousus H; Garcia D; Gibbs H; Kamphuisen PW; Monreal M; Ockelford P; Pabinger I; Verhamme P; Grosso MA; Büller HR; Raskob GE
Thromb Haemost; 2015 Nov; 114(6):1268-76. PubMed ID: 26271200
[TBL] [Abstract][Full Text] [Related]
19. Oral direct factor Xa inhibition with edoxaban for thromboprophylaxis after elective total hip replacement. A randomised double-blind dose-response study.
Raskob G; Cohen AT; Eriksson BI; Puskas D; Shi M; Bocanegra T; Weitz JI
Thromb Haemost; 2010 Sep; 104(3):642-9. PubMed ID: 20589317
[TBL] [Abstract][Full Text] [Related]
20. Prediction of major and clinically relevant bleeding in patients with VTE treated with edoxaban or vitamin K antagonists.
Di Nisio M; Raskob G; Büller HR; Grosso MA; Zhang G; Winters SM; Cohen A
Thromb Haemost; 2017 Apr; 117(4):784-793. PubMed ID: 28151543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
